Doctor Rebecca Taub

Doctor Rebecca Taub

Madrigal Pharmaceuticals, Conshohocken (United States of America)

Rebecca Taub, M.D. has served as Chief Medical Officer and Executive Vice President, Research & Development, and as a member of our Board of Directors, since July 2016. Previously, Dr. Taub served as Chief Executive Officer and as a member of the Board of Directors of privately-held Madrigal Pharmaceuticals. Dr. Taub served as Vice President, Research, Metabolic Diseases at Hoffmann-La Roche from 2004 to 2008 where Dr. Taub oversaw cardiovascular and metabolic diseases. Before becoming a pharmaceutical executive, Dr. Taub was a tenured Professor of Genetics and Medicine at the University of Pennsylvania.

Presentations

In a 36-week placebo-controlled phase 2 trial in patients with non-alcoholic steatohepatitis (NASH), treatment with mgl-3196 (resmetirom) significantly reduces atherogenic lipoprotein particles

Event: ESC Congress 2019

Topic: Drug therapy

Session: Risk Factors and Prevention, Cardiovascular Disease in Special Populations

Access

LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 week study in HeFH patients

Event: ESC Congress 2018

Topic: Drug therapy

Session: Preventive cardiology / Lipids

Access

Doctor Rebecca Taub

Biography

Contributor content

In a 36-week placebo-controlled phase 2 trial in patients with non-alcoholic steatohepatitis (NASH), treatment with mgl-3196 (resmetirom) significantly reduces atherogenic lipoprotein particles

LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 week study in HeFH patients

ESC 365 is supported by